We caught up with Editorial Board member Dr Assaf Hilely (Tel Aviv Medical Center, Tel Aviv, Israel), who talked us through his recent study of non-neovascular age-related macular degeneration with subretinal fluid.
- What prognostic factors are currently used to guide treatment when initiating anti-vascular endothelial growth factor treatment for patients with age-related macular degeneration (AMD) with and without neovascularisation? (00:07)
- What was the rationale for investigating patterns of subretinal fluid in eyes with AMD without neovascularisation? (01:22)
- Could you tell us a little about the aims and design of your recent study? (02:12)
- What were the findings of the study? (03:20)
- What will be the impact of these findings on clinical practice and what future studies are planned? (04:53)
Speaker Disclosure: Dr Assaf Hilely has no financial or non-financial relationships or activities to declare in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of ESCRS 2020.
Share this Video
Related Videos In Macular Degeneration
Usha Chakravarthy, EURETINA 2022: Persistent fluid in neovascular age-related macular degeneration
The Archway study (NCT03677934) was a phase 3, randomized, active treatment–controlled trial for the treatment of nAMD, conducted at 77 study locations in the United States. We caught up with Prof. Usha Chakravarthy (Queen’s University of Belfast, Belfast, Northern Ireland) to discuss the causes of persistent fluid in neovascular age-related macular degeneration and the impact […]
Anat Loewenstein, EURETINA 2022: Home Monitoring for Age-related Macular Degeneration
It was a pleasure to interview Prof. Anat Loewenstein (Tel Aviv Medical Center, Tel Aviv, Israel) on her EURETINA presentation discussing the advantages of home monitoring of age-related macular degeneration, and the results of a study evaluating a new device for home monitoring. The abstract ‘Functional and anatomical options for home monitoring in the era […]
Katerina Prokopiou, ARVO 2022: Therapeutic potential of omega-3 fatty acids supplementation in dry age-related macular degeneration and Stargardt Disease
The clinical outcomes of the MADEOS trial (NCT03297515) is discussed in this touchOPHTHALMOLOGY interview with Dr Katerina Prokopiou (University of Nicosia Medical School, Engomi, Cyprus). Currently, there is no effective treatment available that stops progression or improves vision in patients with dry age-related macular degeneration or Stargardt disease, the MADEOS trial assesses the therapeutic potential of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!